IP Library Granted Patent US 9,173,989
Granted Patent B2
US 9,173,989 · App. 12/086,126 · Granted Nov 3, 2015

Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood

Inventors: Olle Larm (Bromma, SE); Tomas Bergström (Göteborg, SE)
Assignee: EXTHERA MEDICAL CORPORATION
A61M1/3679A61K31/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,173,989
App. No.
12/086,126
Granted
Nov 3, 2015
Kind
B2
Abstract

The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein/and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.

Claims (18)

1. A method for treating a subject in need thereof, by extracorporeal removal of Staphylococcus aureus , said method comprising:

a) contacting said subject's whole blood with heparin immobilized on a solid substrate, said heparin having a terminal residue, wherein heparin immobilization consists of a single covalent link of said terminal residue to said solid substrate by covalent end-point attachment, under conditions allowing binding of said Staphylococcus aureus in said subject's whole blood sample to the heparin;

b) separating the whole blood from the solid substrate;

c) recovering said whole blood containing a reduced amount of said Staphylococcus aureus ; and

d) reintroducing into said subject said whole blood containing a reduced amount of said Staphylococcus aureus.

2. The method according to claim 1 , wherein said solid substrate comprises microparticles.

3. The method according to claim 1 , wherein said solid substrate comprises fibers.

4. The method according to claim 1 , wherein the material of said solid substrate is at least one member selected from the group consisting of glass, cellulose, cellulose acetate, chitin, chitosan, crosslinked dextran, crosslinked agarose, polypropylene, polyethylene, polysulfone, polyacrylonitrile, silicone, Teflon and polyurethanes.

5. A method for extracorporeal removal of a pathogenic microbe, wherein said pathogenic microbe is Staphylococcus aureus , from human whole blood, said method comprising:

a) contacting human whole blood with heparin immobilized on a solid substrate by blood flow through a device comprising said solid substrate, said heparin having a terminal residue, wherein heparin immobilization consists of a single covalent link of said terminal residue to said solid substrate by covalent end-point attachment, under conditions allowing binding of said pathogenic microbe, wherein said pathogenic microbe is Staphylococcus aureus in said human whole blood sample to the heparin;

b) separating the whole blood from the solid substrate; and

c) recovering said whole blood containing a reduced amount of said pathogenic microbe, wherein said pathogenic microbe is Staphylococcus aureus.

6. The method according to claim 5 , wherein said solid substrate comprises microparticles.

7. The method according to claim 5 , wherein said solid substrate comprises fibers.

8. The method according to claim 5 , wherein the material of said solid substrate is at least one member selected from the group consisting of glass, cellulose, cellulose acetate, chitin, chitosan, crosslinked dextran, crosslinked agarose, polypropylene, polyethylene, polysulfone, polyacrylonitrile, silicone, Teflon and polyurethanes.

9. The method according to claim 5 , wherein said method comprises a continuous loop with the human bloodstream further comprising extracting whole blood from a human before contacting step and reintroducing into said human said blood containing a reduced amount of said pathogenic microbe.

10. The method according to claim 1 , wherein said solid substrate comprises a disposable column.

11. The method according to claim 5 , wherein said solid substrate comprises a disposable column.

Assignments (4)
CHANGE OF ADDRESS Recorded Jun 12, 2020
From: EXTHERA MEDICAL CORPORATION
To: EXTHERA MEDICAL CORPORATION
Reel/Frame 052927/0321 →
CHANGE OF NAME Recorded Mar 14, 2014
From: EXTHERA MEDICAL LLC
To: EXTHERA MEDICAL CORPORATION
Reel/Frame 032449/0630 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2011
From: EXTHERA AB
To: EXTHERA MEDICAL, LLC
Reel/Frame 027042/0930 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2008
From: LARM, OLLE; BERGSTROM, TOMAS
To: EXTHERA AB
Reel/Frame 021506/0334 →
Priority Claims (1)
SE 0502750 · Dec 13, 2005 · national
Continuity (1)
Related Publication 20090136586A1 · May 28, 2009